Written By: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch
Download Here

Description Venetoclax is as selective inhibitor of B cell lymphoma-2 (BCL-2). Inhibition of BCL-2 by venetoclax results in cytotoxic activity in tumor cells that overexpress BCL-2 by restoring apoptosis. Venetoclax is indicated in Acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL) and small lymphocytic leukemia (SLL) in patients with or without chromosome 17p deletion.  During the ramp-up phase, patients are titrated on venetoclax and assigned a risk category based on tumor burden and potential for developing Tumor Lysis Syndrome (TLS).  These risk stratifications create special challenges for the dispensing of venetoclax.   Some medium-risk and all high-risk patients may require hospital admission during titration; communication between the oncology pharmacist, nurse, lab technicians, hematologist, and the patient will ensure the recommended administration guidelines and lab monitoring are followed to ensure patient safety and best outcomes.

Continue reading Venetoclax Risk Stratification, Dosing, and Dispensing Procedure

Read More